Renal Outcome in High Risk of Kidney Failure in Heart Failure Patient With and Without Tolvaptan, Randomized Controlled Trial

avamindradhiraj University Research Fund0 个研究点目标入组 88 人开始时间: 2022年7月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1.hospitalized heart failure patient
•2.chronic kidney disease stage 3-4
•3.in case of absence baseline renal function
•3.1 patient with creatinine more than or equal 2mg/dl at admission
•3.2 patient with creatinine 1.1 to less than 2mg/dl at admission with equal or more than 70 years old
•4.more than 18 years old

•1.Acute Kidney Injury Network stage 3 on admission
•2.autosomal dominant polycystic kidney disease
•3.pregnancy or breast feeding
•4.cirrhosis or liver failure or transaminitis which AST, ALT more than 2times of upper normal limit
•5.serum sodium more than 145mEq/L
•6.concomitant use with CYP3A inhibitor such as ketoconazole, itraconazole, fluconazole, clarithromycin, erythromycin, indinavir, ritonavir, diltiazem, verapamil
•7.concomitant use with CYP3A inducer such as rifampin, barbiturate, phenytoin, carbamazepine
•8.concomitant use with P-gp inhibitor such as cyclosporin
•9.history of drug allergy with tolvaptan or furosemide
•10.unstable vital sign
•11.postcardiac arrest
•12.unable to access tolvaptan within 24 hours after admission

发起方

avamindradhiraj University Research Fund